Enterprise Value

3.551B

Cash

386.2M

Avg Qtr Burn

-36.27M

Short % of Float

20.92%

Insider Ownership

17.12%

Institutional Own.

83.03%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Sunosi® (solriamfetol) Details
Mental health, Excessive daytime sleepiness

Approved

Quarterly sales

NDA

Resubmission

NDA

Submission

Solriamfetol Details
Major depressive disorder

Phase 3

Data readout

Solriamfetol Details
Binge eating disorder

Phase 3

Data readout

Solriamfetol Details
Attention deficit hyperactivity disorder

Phase 3

Data readout

AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details
Alzheimer's disease

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 3

Update

Solriamfetol Details
Shift work disorder

Phase 3

Initiation

Phase 2/3

Initiation